Vanguard Group
CTKB icon

Vanguard Group’s Cytek Biosciences CTKB Stock Holding History

Vanguard Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$37.8M Buy
7,475,477
+541,973
+8% +$2.52M ﹤0.01% 2316
2025
Q3 		$24.1M Sell
6,933,504
-831,634
-11% -$3.12M ﹤0.01% 2536
2025
Q2 		$26.4M Sell
7,765,138
-1,856,870
-19% -$6.19M ﹤0.01% 2429
2025
Q1 		$38.6M Sell
9,622,008
-2,094,835
-18% -$10.9M ﹤0.01% 2207
2024
Q4 		$76M Sell
11,716,843
-61,211
-0.5% -$365K ﹤0.01% 1979
2024
Q3 		$65.3M Buy
11,778,054
+31,876
+0.3% +$181K ﹤0.01% 2065
2024
Q2 		$65.5M Sell
11,746,178
-266,627
-2% -$1.6M ﹤0.01% 2043
2024
Q1 		$80.6M Buy
12,012,805
+122,105
+1% +$966K ﹤0.01% 1968
2023
Q4 		$108M Buy
11,890,700
+811,279
+7% +$5.11M ﹤0.01% 1825
2023
Q3 		$61.2M Buy
11,079,421
+461,142
+4% +$3.7M ﹤0.01% 2035
2023
Q2 		$90.7M Buy
10,618,279
+2,732,791
+35% +$24.5M ﹤0.01% 1908
2023
Q1 		$72.5M Buy
7,885,488
+114,421
+1% +$1.23M ﹤0.01% 1990
2022
Q4 		$79.3M Buy
7,771,067
+83,562
+1% +$1.12M ﹤0.01% 1932
2022
Q3 		$113M Buy
7,687,505
+1,413,703
+23% +$18.4M ﹤0.01% 1716
2022
Q2 		$67.3M Sell
6,273,802
-78,288
-1% -$779K ﹤0.01% 2045
2022
Q1 		$68.5M Buy
6,352,090
+5,140,344
+424% +$69.4M ﹤0.01% 2140
2021
Q4 		$19.8M Buy
1,211,746
+15,374
+1% +$322K ﹤0.01% 2847
2021
Q3 		$25.6M Buy
+1,196,372
New +$28.1M ﹤0.01% 2711

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group's CTKB Position: Q4 2025 in Review

Vanguard Group increased its Cytek Biosciences (CTKB) stake by 7.8% in Q4 2025, buying an estimated $2.52M and bringing the position to 7,475,477 shares worth $37.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

Vanguard Group first reported a position in CTKB in Q3 2021 and has held it in 18 quarters since. The position peaked at $113M in Q3 2022. 155 funds tracked by Wall St. Rank hold CTKB as of Q4 2025.

  • Vanguard Group held 7,475,477 shares of Cytek Biosciences worth $37.8M as of Q4 2025.
  • Vanguard Group bought 541,973 Cytek Biosciences shares in Q4 2025, an estimated $2.52M.
  • Cytek Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2316 holding.
  • Vanguard Group first reported a position in Cytek Biosciences in Q3 2021 and has held it in 18 quarters since.
  • Vanguard Group's Cytek Biosciences position peaked at $113M in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.